Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Hepatic encephalopathy (HE) is the leading cause of mortality in patients suffering from acute liver failure and also in those patients suffering from liver cirrhosis and associated with end stage liver disease. The person suffering from hepatic encephalopathy loses the ability to metabolize ammonia, which results in the buildup of ammonia in various tissues and organs of the body. Moreover, ammonia crosses the blood–brain barrier and thus cause neurocognitive impairment. Hepatic encephalopathy can be classified into two types: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE), out of which, overt hepatic encephalopathy is associated with high rates of mortality and poor quality of life, as compared to covert hepatic encephalopathy (CHE).

Global Hepatic Encephalopathy Market - Impact of the Coronavirus (COVID-19) Pandemic

COVID-19 pandemic is expected to hamper growth of the global hepatic encephalopathy market during the forecast period. For instance, according to the National Center for Biotechnology Information, 23rd September 2020, the coronavirus (COVID-19) pandemic led to the imposing of lockdown in various countries across the globe, which has impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the pandemic. The lockdowns in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatient’s visits, among others.

Moreover, according to the same source, the pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the healthcare segment of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. For instance, according to U.S. Food and Drug Administration (FDA), 18th September 2020, in the U.S. alone, there were 148 antibiotic shortages from 2001 to 2013, and a recent penicillin shortage affected at least 39 countries throughout Europe, the Americas, and Asia Pacific. As of June 29, 2020, 10.5% of all drug shortages listed by the U.S. FDA were antibiotics.

The global hepatic encephalopathy is estimated to be valued at US$ 355.4 Mn in 2020 and is expected to exhibit a CAGR of 5.3% over the forecast period (2020-2027).

Figure 1: Global Hepatic Encephalopathy Market Share (%) Analysis, By Drug Class, 2020

Hepatic Encephalopathy  | Coherent Market Insights

Market players are indulged in conducting research and development for testing the safety and efficacy of drug candidate for the treatment of liver diseases and this is expected to drive growth of the global hepatic encephalopathy market over the forecast period.

The increasing research and development activities for the treatment of liver diseases is expected to drive the global hepatic encephalopathy market growth over the forecast period. For instance, in March 2020, Bausch Health Companies Inc. announced positive results for the Phase II study for the combination therapy, which included rifaximin in combination with the lactulose. The trial was carried out to study the effectiveness of combination therapy for the treatment of Overt Hepatic Encephalopathy (OHE). Moreover, in January 2017, Ocera Therapeutics, Inc. announced positive results for its STOP-HE Phase IIb Study which determined the safety and efficacy of Ornithine Phenylacetate (OCR-002), when administered intravenously, in hospitalized patients with hepatic encephalopathy (HE).

request-sample

Hepatic Encephalopathy Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 355.4 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.3 % 2027 Value Projection: US$ 511.6 Million
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Antibiotics, Laxatives, L-ornithine L-aspartate, Others.
  • By Route of Administration: Oral, Intravenous, Rectal.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd.

Growth Drivers:
  • Increasing research and development activities
  • Increasing submissions of abbreviated new drug application (ANDA)
Restraints & Challenges:
  • High cost of treatment

Market players are focused in submitting the abbreviated new drug application (ANDA) to the regulatory authorities for gaining approval for the generic drug for the treatment of hepatic encephalopathy, which is expected to spur growth of the hepatic encephalopathy market over the forecast period.

Market players are involved in submitting the abbreviated new drug application (ANDA), which is an important step for launching new drugs in the market. For instance, in February 2016, Allergan plc announced that the U.S. Food and Drug Administration (FDA) accepted its abbreviated new drug application (ANDA) for gaining approval to market generic rifaximin tablets, 550 mg, which is indicated for the treatment of overt hepatic encephalopathy (HE) recurrence in adults.

Global Hepatic Encephalopathy Market - Restraints

High cost of rifaximin for the treatment of hepatic encephalopathy is one of the factors that is expected to restrain growth of the market. For instance, according to the National Center for Biotechnology Information: 2017, hepatic encephalopathy is the second most common reason for hospitalization in patients suffering from liver cirrhosis, in the U.S., after ascites. According to the same source, the national expenditures for U.S., related to hospitalizations for hepatic encephalopathy have been estimated to range from around US$ 1 billion per year to above US$ 7 billion per year. Moreover, according to the World Journal of Gastrointestinal Pharmacology and Therapeutics: August 2012, various research studies would propose long-term, probably life-long, rifaximin therapy for preventing hepatic encephalopathy recurrence, as liver cirrhosis is an irreversible disease. The above factor is expected to restrain the global hepatic encephalopathy market over the forecast period.

Global Hepatic Encephalopathy Market – Regional Analysis

North America is expected to dominate the global hepatic encephalopathy market, owing to the increasing prevalence of liver diseases in the region. For instance, in the U.S., according to the statistics provided by the Centers for Disease Control and Prevention (CDC), in 2017, in the U.S.,around 4.5 million adults were diagnosed with liver diseases. The number of deaths due to chronic liver disease and cirrhosis accounted for 40,545 in 2017 in the U.S. Furthermore, according to the data published in American Liver Foundation in 2017, hepatitis C infection caused by hepatitis C virus (HCV), is the leading cause of liver cirrhosis in the U.S., followed by alcohol consumption related cirrhosis, contributing to around 20% to 25% cases of liver cirrhosis.

Moreover, Europe is also an emerging hepatic encephalopathy market, owing to the increase in the research and development activities for the treatment and management of liver diseases. For instance, in 2019, ALIVER, a research and awareness project from the European Union's Horizon 2020 research and innovation program received funding of US$ 8.5 million for the project. ALIVER consortium developed a novel and innovative liver dialysis machine that will help the liver to naturally regenerate and to keep patients alive and healthy until a liver donor is available. The project was initiated on January 1, 2017 and ended on September 30, 2020.

Figure 2: Global Hepatic Encephalopathy Market Value (US$ Mn), by Region, 2020

Hepatic Encephalopathy  | Coherent Market Insights

Global Hepatic Encephalopathy Market – Competitive Landscape

Major players operating in the global hepatic encephalopathy market include ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd.

Hepatic encephalopathy (HE) is the complication of advanced liver disease. Hepatic encephalopathy is a major challenge to the healthcare system due to frequent hospital contacts and admissions. Hepatic encephalopathy can be further divided into type A, type B, and type C that results from acute liver failure, portosystemic encephalopathy (PSS), and liver cirrhosis, respectively.

Market Dynamics

Key players are indulged in conducting clinical trials for the development of new therapeutic products for the treatment for liver diseases, which is expected to drive the global hepatic encephalopathy market growth over the forecast period. For instance, in December 2019, Kaleido Biosciences, Inc., a clinical-stage healthcare company announced positive results from a proof-of-concept clinical study, in which they used KB174, a novel microbiome metabolic therapy (MMT) in combination with a 15N-labeled tracer, a biomarker of microbiome ammonia production, in patients with liver cirrhosis. The treatment reduced the 15N urinary output and was well tolerated among the patients.

Market players are engaged in launching new products, in order to expand their market share, which is expected to spur growth of the market over the forecast period. For instance, in April 2015, Lupin Pharma Canada Limited, a subsidiary of Lupin Limited, launched Zaxine, indicated for the treatment of hepatic encephalopathy, under a strategic licensing agreement with the Salix Pharmaceuticals Inc. The agreement granted Lupin Pharma Canada Limited exclusive rights for the promotion, distribution, and marketing of Zaxine in Canada.

Key features of the study:

  • This report provides an in-depth analysis of global hepatic encephalopathy market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020 – 2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global hepatic encephalopathy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the hepatic encephalopathy market.

Detailed Segmentation:

  • Global Hepatic Encephalopathy Market, By Drug Class:
    • Antibiotics
    • Laxatives
    • L-ornithine L-aspartate
    • Others
  • Global Hepatic Encephalopathy Market, By Route of Administration:
    • Oral
    • Intravenous
    • Rectal
  • Global Hepatic Encephalopathy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hepatic Encephalopathy Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
      • By Drug Class:
        • Antibiotics
        • Laxatives
        • L-ornithine L-aspartate
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Rectal
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Antibiotics
        • Laxatives
        • L-ornithine L-aspartate
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Rectal
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Antibiotics
        • Laxatives
        • L-ornithine L-aspartate
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Rectal
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Antibiotics
        • Laxatives
        • L-ornithine L-aspartate
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Rectal
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Antibiotics
        • Laxatives
        • L-ornithine L-aspartate
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Rectal
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Antibiotics
        • Laxatives
        • L-ornithine L-aspartate
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Rectal
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • ASKA Pharmaceutical Co.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Cosmo Pharmaceuticals N.V.
    • Lupin Limited
    • Kaleido Biosciences
    • Kannalife Sciences, Inc.
    • Bausch Health Companies Inc.
    • Ferring Pharmaceuticals Inc.
    • Mallinckrodt Pharmaceuticals
    • Umecrine Cognition AB
    • Norgine B.V.
    • Abbott Laboratories
    • QR Science and Technology Development Co. Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Epidemiology
    • Key Developments
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
  4. Global Hepatic Encephalopathy Market - Covid – 19 Impact Analysis
    • During Covid-19 Market Situation
    • Supply Side and Demand Side Analysis
    • Overall Impact on Countries
  5. Global Hepatic Encephalopathy Market, By Drug Class, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Laxatives
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • L-ornithine L-aspartate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  6. Global Hepatic Encephalopathy Market, By Route of Administration, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Rectal
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  7. Global Hepatic Encephalopathy Market, By Distribution Channel, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  8. Global Hepatic Encephalopathy Market, By Region, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • ASKA Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Cosmo Pharmaceuticals N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Lupin Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Kaleido Biosciences
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Kannalife Sciences Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Bausch Health Companies Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Ferring Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Mallinckrodt Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Umecrine Cognition AB
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Norgine B.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • QR Science and Technology Development Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 27 figures on "Global Hepatic Encephalopathy Market” - Global Forecast to 2027”.

FAQgrowicon

Frequently Asked Questions

The global hepatic encephalopathy market is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).
The global hepatic encephalopathy market is estimated to be valued at US$ 355.4 million in 2020.
ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd. are some of the prominent players operating in the global hepatic encephalopathy market.
The global hepatic encephalopathy market is expected to be valued at US$ 511.6 million in 2027.
Antibiotics is the major drug class in the global hepatic encephalopathy market.
North America is the prominent region in the global hepatic encephalopathy market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.